Kiersten Stead

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Part of Verint Systems, Inc., Panop.com, Inc. develops real-time interaction technology across Web, WAP devices, e-mail, and call center interaction points. The company is based in Palo Alto, CA. The company was founded by Kim H. Stanley, Matthew Rabinowitz. Panop.com was acquired by Broadbase Software, Inc. on September 21, 2000 for $47.71 million.

5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US.

KTB Network Co., Ltd. (Venture Capital) is a venture capital subsidiary of Daol Investment Co., Ltd. founded in 1981. KTB Network Co., Ltd. (Venture Capital) is headquartered in Seongnam, South Korea with offices in Shanghai, Palo Alto and Singapore.

Neuroptika, Inc. operates as biotechnology company which develops drugs for eye diseases and nerves regeneration. The company was founded by Chiho Fukiage and in November 2018 and is headquartered in Cambridge, MA.

MyOme, Inc. is a clinical whole genome analysis platform company that helps families understand their risk for inherited diseases. Certified under the Clinical Laboratory Improvement Amendments (CLIA), MyOme is based in San Carlos, CA. The company is a leader in polygenic modeling and leverage the power of the whole genome for a lifetime of actionable insights. In 2017, a group of geneticists, clinicians, biologists, engineers, parents, daughters, and sons formed MyOme believing that everyone can benefit from their services. MyOme maintains internet-accessible web sites, interactive user interfaces, mobile applications, and application programming interfaces for healthcare providers to complete the test requisition form (TRF) on their health system's interface. The company's proactive health report includes 78 genes identified as medically actionable by the American College of Medical Genetics and Genomics, providing a more complete picture of disease risk through clinical grade whole genome sequencing (up to 30x) and analysis. The company was founded by Matthew Rabinowitz, Kate Im, Akash Kumar, and Oren Schaedel. The CEO is Premal S. Shah.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.